Clinical Trial Update: A Trial of Erbitux for Recurrent and Metastatic Mucinous Gastrointestinal Adenocarcinoma Involving the Peritoneal Surfaces [Phase 2]

View source ↗

Summary

A Phase 2 trial of cetuximab (Erbitux) for recurrent and metastatic mucinous gastrointestinal adenocarcinoma involving the peritoneal surfaces has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucinous Gastrointestinal Adenocarcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Mucinous Gastrointestinal Adenocarcinoma | Phase 2 | Status: COMPLETED